150 related articles for article (PubMed ID: 35657056)
1. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
[TBL] [Abstract][Full Text] [Related]
2. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
[TBL] [Abstract][Full Text] [Related]
4. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
[TBL] [Abstract][Full Text] [Related]
5. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
[TBL] [Abstract][Full Text] [Related]
6. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
[TBL] [Abstract][Full Text] [Related]
7. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Evolution of Acute Oral Complications in Patients Undergoing Radiochemotherapy Treatment for Head and Neck Squamous Cell Carcinoma.
Palmieri M; Sarmento DJS; Falcão AP; Martins VAO; Brandão TB; Morais-Faria K; Ribeiro ACP; Hasséus B; Giglio D; Braz-Silva PH
Ear Nose Throat J; 2021 Sep; 100(5_suppl):449S-455S. PubMed ID: 31619067
[TBL] [Abstract][Full Text] [Related]
9. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; van der Schaaf A; van den Heuvel ER; Doornaert P; van Luijk P; Vissink A; van der Laan BF; Leemans CR; Bijl HP; Christianen ME; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):101-6. PubMed ID: 22516776
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
[TBL] [Abstract][Full Text] [Related]
11. NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.
Hansen CR; Friborg J; Jensen K; Samsøe E; Johnsen L; Zukauskaite R; Grau C; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Eriksen JG; Overgaard J
Acta Oncol; 2019 Oct; 58(10):1410-1415. PubMed ID: 31432744
[No Abstract] [Full Text] [Related]
12. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
13. LASSO NTCP predictors for the incidence of xerostomia in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Lee TF; Liou MH; Huang YJ; Chao PJ; Ting HM; Lee HY; Fang FM
Sci Rep; 2014 Aug; 4():6217. PubMed ID: 25163814
[TBL] [Abstract][Full Text] [Related]
14. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
15. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M;
Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686
[TBL] [Abstract][Full Text] [Related]
16. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
17. Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.
Mazzola R; Ferrera G; Alongi F; Mannino M; Abbate B; Cucchiara T; Iacoviello G; Sciumè F; Di Paola G; Federico M; Blasi L; Lo Casto A; Lagalla R; Messana D
Radiol Med; 2015 Aug; 120(8):753-8. PubMed ID: 25663551
[TBL] [Abstract][Full Text] [Related]
18. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
[TBL] [Abstract][Full Text] [Related]
19. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F
Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
Lee TF; Fang FM
Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
